Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice

A total of 1028 hypercholesterolaemic men and women aged 18-75 participated in an open label, randomised, parallel group, 6-month treatment-to-target study conducted in 240 general practices throughout Australia. The study co mpared atorvastatin monotherapy with simvastatin monotherapy or, if necessa ry, with the combination of simvastatin and cholestyramine in terms of thei r abilities to achieve a plasma total cholesterol target of < 5.0 mmol/l. T he initial daily dose of each drug was 10 mg. If the target was not achieve d, the dose was doubled at 6 week intervals to a maximum daily dose of 80 m g atorvastatin or 40 mg simvastatin, with the simvastatin supplemented if n ecessary with 4 g cholestyramine. The percentage of patients achieving the target at 10 and 20 mg doses of atorvastatin were comparable to 20 and 40 m g of simvastatin, respectively. Despite relatively high baseline levels of plasma total cholesterol (mean levels of 7.41 and 7.31 mmol/l in the atorva statin and simvastatin groups, respectively) the majority of patients in ea ch group achieved the plasma total cholesterol target of < 5.0 mmol/l. Trea tment with atorvastatin achieved the target in 83% of patients, while simva statin (or simvastatin plus cholestyramine) achieved the target in 66% of t he patients (P < 0.005). The target was achieved with 10 mg atorvastatin in 38% of patients and with 10 mg simvastatin in 26% of cases (P < 0.005). In patients whose baseline cholesterol levels were between 5.6 and 6.5 mmol/l , 95% of the atorvastatin group and 86% of the simvastatin group reached th e target. Even with baseline cholesterol levels between 7.6 and 8.5 mmol/l, the target was reached in 78% of the atorvastatin group and 61% of the sim vastatin group. It is thus realistic for general practitioners to expect th e majority of their at risk patients to achieve target plasma cholesterol l evels that have been shown in population studies to be associated with rela tively low rates of coronary heart disease. These targets are achieved in s ignificantly more patients and at lower mg doses with atorvastatin than sim vastatin. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.